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Cartilage grafts generated using conventional static tissue engineering strategies are characterised by low
cell viability, suboptimal hyaline cartilage formation and, critically, inferior mechanical competency, which
limit their application for resurfacing articular cartilage defects. To address the limitations of conventional
static cartilage bioengineering strategies and generate robust, scaffold-free neocartilage grafts of human
articular chondrocytes, the present study utilised custom-built microfluidic perfusion bioreactors with inte-
grated ultrasound standing wave traps. The system employed sweeping acoustic drive frequencies over the
range of 890 to 910 kHz and continuous perfusion of the chondrogenic culture medium at a low-shear
flow rate to promote the generation of three-dimensional agglomerates of human articular chondrocytes,
and enhance cartilage formation by cells of the agglomerates via improved mechanical stimulation and
mass transfer rates. Histological examination and assessment of micromechanical properties using
indentation-type atomic force microscopy confirmed that the neocartilage grafts were analogous to native
hyaline cartilage. Furthermore, in the ex vivo organ culture partial thickness cartilage defect model, implan-
tation of the neocartilage grafts into defects for 16 weeks resulted in the formation of hyaline cartilage-like
repair tissue that adhered to the host cartilage and contributed to significant improvements to the tissue
architecture within the defects, compared to the empty defects. The study has demonstrated the first
successful application of the acoustofluidic perfusion bioreactors to bioengineer scaffold-free neocartilage
grafts of human articular chondrocytes that have the potential for subsequent use in second generation
autologous chondrocyte implantation procedures for the repair of partial thickness cartilage defects.1. Introduction
Osteoarthritis (OA), the most common form of arthritis in
the western world, is a degenerative joint disease that is
characterised by the deterioration and progressive loss of
articular cartilage. Early stages of OA are associated with the
development of clefts and fissures in the articular cartilage
surface that resemble partial thickness defects or chondral
defects. Partial thickness defects are unable to heal spontane-
ously because the lesions do not extend into the marrow
spaces of the subchondral bone and cannot gain access to thebone marrow skeletal stem cells to promote repair.1 It is
therefore critical to repair these defects in the early stages of
OA because, if left untreated, the fibrillated lesions typically
grow larger and deeper over time, and contribute to progres-
sive articular cartilage degeneration and joint immobilisation.
Currently, there are no effective pharmacological agents that
are able to promote comprehensive healing of articular carti-
lage defects.
Surgical interventions for functional restoration of articu-
lar cartilage defects include reparative bone marrow stimula-
tion techniques such as abrasion arthroplasty, drilling,
microfracture, and restorative approaches such as autolo-
gous chondrocyte implantation (ACI), osteochondral auto/
allografts, periosteal/perichondral grafts.2 Although these
interventions provide symptomatic relief and improve joint
function temporarily, to date, no technique has been
completely successful in restoring/regenerating damaged
articular cartilage to its native state. This is because the
repair tissue that is generated is often fibrocartilaginous in
nature, and therefore lacks the mechanical competency of
hyaline articular cartilage. Moreover, inability of the, 2014, 14, 4475–4485 | 4475
Lab on a ChipPaperimplanted graft/fibrocartilaginous repair tissue to integrate
with the surrounding native cartilage contributes to graft
failure and further degeneration of the joint.
Attempts to improve the outcomes of cell-based transplan-
tation methods, such as ACI, have therefore focused on the
application of autologous chondrocytes seeded onto collagen
scaffolds, in matrix-induced ACI, and three-dimensional (3-D)
cartilaginous constructs, in second (II) generation ACI, for
the repair of articular cartilage defects.3–5 This, in turn, has
led to considerable interest in the development of effective
scaffold-free and scaffold-based tissue engineering strategies
for generating cartilage grafts. Scaffold-free modalities have
been employed to stimulate chondrogenic differentiation and
cartilage formation via cell–cell and cell–matrix interactions
in high-density chondrospheres and multilayer articular
chondrocyte sheets.6,7 In contrast to the scaffold-free modali-
ties, which require cells to develop their own structure and
matrix during development, strategies harnessing scaffolds
provide cells with an effective 3-D framework that supports
tissue assembly and growth. However, the successful applica-
tion of biomaterials in tissue engineering, including cartilage
bioengineering, requires careful consideration of their 3-D
architecture, biofunctionality, biocompatibility, biomechanics,
degradation rates and immunogenicity of the degradation
products.8,9
Tissue grafts generated using conventional static tissue
engineering strategies are often characterised by appreciable
necrosis and suboptimal tissue formation due to poor nutri-
ent mass transfer rates and oxygen diffusion in almost any
graft site with diffusion distance more than 1 mm.10 To
address some of the issues related to suboptimal tissue for-
mation and cell viability in constructs generated using 3-D
static culture techniques, tissue engineering strategies have
increasingly applied bioreactors, which provide a closely
monitored environment and, critically, biomechanical stimuli
such as hydrodynamic shear stress, hydrostatic pressure and
dynamic compression for optimal tissue growth.11 Bioreac-
tors have been used to culture a wide range of cells, namely
stem cells, chondrocytes, osteoblasts, keratinocytes, hepato-
cytes, cardiomyocytes and myofibroblasts, for a diverse array
of applications including cartilage, bone, skin, liver and car-
diovascular tissue engineering.11,12 In particular, perfusion
flow bioreactors have been frequently used for cartilage tissue
engineering due to their ability to enhance cartilage forma-
tion by chondrocytes and mesenchymal cell populations
through the application of mechanical stimuli in the form of
fluid flow-induced hydrodynamic shear stresses, and improve-
ment of mass transfer rates of metabolites and oxygen.13,14
The safe use of ultrasound and its diverse diagnostic and
therapeutic applications are widely acknowledged.15–17 Low
intensity pulsed ultrasound has been demonstrated to accel-
erate the repair of damaged cartilage in a number of animal
studies. Low intensity ultrasound typically refers to field
intensities below 1 W cm−2 that are applied either in continu-
ous or burst (pulsed) mode.18,19 A variation of low intensity
ultrasound, referred to as low intensity diffuse ultrasound,4476 | Lab Chip, 2014, 14, 4475–4485involves scattering of acoustic waves generated by the trans-
ducer throughout the chamber.20 In the rat model of papain-
induced knee osteoarthritis, the application of ultrasound
was shown to enhance cartilage repair in the early stage of
the disease, and arrest further deteriorative cartilage damage
in the later stage of osteoarthritis.21 Daily low intensity
pulsed ultrasound was demonstrated to have a significant
positive effect on the repair of full thickness osteochondral
defects created in the patellar grooves of rabbits.22 In a
canine model, low intensity pulsed ultrasound enhanced the
incorporation of autologous osteochondral plugs by improv-
ing the characteristics of the interface repair tissue and its
integration with the adjacent cartilage.23
In the field of tissue engineering, ultrasound has predomi-
nantly been applied in the form of low intensity ultrasound
to stimulate cells, and ultrasonic standing wave fields to
generate acoustic traps, which can spatially manipulate cells,
proteins and microbeads.24 Specifically for cartilage tissue
engineering, the application of low intensity ultrasound to
enhance chondrogenic differentiation of bone marrow
mesenchymal stem cells and chondrocytes, cultured in a
variety of 3-D environments, has been documented in a num-
ber of studies.25–29 However, ultrasonic cell trapping, a non-
destructive and non-invasive cell manipulation technique,30
is a relatively less exploited application of ultrasound for car-
tilage tissue engineering. When a fluid containing a suspen-
sion of cells is exposed to an ultrasonic standing wave field
in a chamber/trap, the acoustic radiation force arising from
the scattering of the acoustic waves on the cells directs the
motion (i.e. acoustophoresis) of cells typically to areas of
minimum pressure, referred to as pressure nodes, and facili-
tates their aggregation into multicellular clusters.31–33 Fur-
thermore, it is possible to drive ensembles of cells into
geometric formations, including linear clusters and planar
(2-D) sheets, by appropriately shaping the resonant wave field
within the ultrasonic trap, and also levitate the multicellular
aggregates away from the influence of the solid substrate.34,35
The present study applied a novel approach that com-
bined bioreactor technology with ultrasonic cell trapping to
bioengineer 3-D, scaffold-free neocartilage grafts of human
articular chondrocytes in custom-built microfluidic perfusion
bioreactors with integrated ultrasound standing wave traps
(USWT). The neocartilage grafts were then examined for their
potential to repair partial thickness chondral defects. The
study has demonstrated the first successful application of the
acoustofluidic perfusion bioreactor for bioengineering scaf-
fold-free, hyaline cartilage-like explants of human articular
chondrocytes. Following implantation into partial thickness
chondral defects, the bioengineered explants generated
hyaline cartilage-like repair tissue that integrated closely
with the surrounding host articular cartilage and contributed
to significant improvements to the tissue architecture within
the defects. The neocartilage grafts, therefore, have the
potential for application in restorative surgical procedures,
such as II generation ACI, to repair early-stage articular carti-
lage damage and limit further cartilage degeneration.This journal is © The Royal Society of Chemistry 2014
Lab on a Chip Paper2. Materials and methods
Most chemicals and reagents were purchased from
Invitrogen/Life Technologies Ltd. (Paisley, UK) and Sigma-Aldrich
(Gillingham, UK) unless specified otherwise.
2.1 Isolation of human articular chondrocytes (HACs)
Femoral head samples were obtained from 4 haematologically
normal osteoarthritic individuals (3 female and 1 male, mean
age: 80 years) following routine total hip replacement surgery
for late-stage OA at Southampton General Hospital. Only
tissue that would have been discarded was used in this
study with approval of the Southampton and South West
Hampshire Research Ethics Committee (ref no. 194/99/1 &
210/01). HACs were isolated by sequential enzymatic diges-
tion of deep-zone articular cartilage pieces dissected from
femoral heads, as explained previously.36 In brief, cartilage
pieces were sequentially digested with 500 μg ml−1 trypsin-
EDTA for 30 min, 1 mg ml−1 hyaluronidase for 15 min and
10 mg ml−1 collagenase B (Roche Diagnostics, Burgess Hill, UK)
overnight on a rotating mixer at 37 °C. Isolated chondrocytes
were cultured to confluence in monolayer cultures in α-MEM
supplemented with 10% (v/v) FCS, 100 units ml−1 penicillin,
100 μg ml−1 streptomycin and 100 μM ascorbate 2-phosphate.
Cultures were maintained in humidified atmosphere at
37 °C, 5% CO2 and 21% O2. Passage 1 cells were utilised for
the experiments.
2.2 Fabrication of perfusion bioreactors with integrated
USWT/acoustofluidic perfusion bioreactors and their
application for generation of neocartilage grafts of HACs
The acoustofluidic perfusion bioreactors were custom-built
using commercially available rectangular glass capillaries
(VitroCom 4608-100, CM Scientific, Silsden, UK) and polydi-
methylsiloxane (PDMS) connectors cast from acrylic moulds
(Fig. 1a). The glass capillaries functioned efficiently as highly
resonant cavities,37–39 and it was possible to autoclave them
along with the non toxic PDMS. A set of 3 resonant chambers
were fabricated from the rectangular glass capillaries (length
5 cm, ID 0.8 × 8 mm2, wall thickness 0.54 mm) and a ceramic
piezoelectric transducer (PZT) (Ferroperm PZ26, Kvistgaard,
Denmark; 10 × 8 × 1 mm3) was glued (Epoxy 353ND, Epotek,
Billerica, MA, USA) to each chamber. Wires soldered to the
electrodes on the transducer were connected to a custom-
made amplifier (LT1210 IC, RS Components, Corby, UK) that
was driven by a signal generator (TG200, TTi, Huntingdon, UK).
The transducer generated an ultrasonic standing wave
field in the lumen of the capillary, with the upper glass
surface acting as a reflector. An impedance spectrum was
used in conjunction with a transfer impedance model to
predict the resonant frequencies of the system.40,41 The half-
wavelength resonance of the cavity was found at 897, 899 and
902 kHz for the three devices respectively. The half-
wavelength resonance had a pressure node in the centre of
the chamber and was observed to i) promote the formationThis journal is © The Royal Society of Chemistry 2014of a 3-D multicellular agglomerate by rapid aggregation at
the pressure node of HACs introduced into the chamber, and
ii) levitate the agglomerate in the lumen of the chamber
above the transducer away from the influence of the solid
substrate (Fig. 1b). The voltage drop method was used to
assess the acoustic pressure amplitude;31 a range of locations
over the transducer were examined with average acoustic
pressure amplitude of 17 ± 5.1 kPa V−1. The generator was
adjusted to create a voltage of 10 Vpp (peak-to-peak voltage)
across the transducer (average over sweep range). In addition
to the primary potential energy gradients found perpendicu-
lar to the transducer, smaller forces caused by gradients in
the kinetic energy density parallel to the transducer created
localised trapping forces.42 These forces assisted agglomerate
formation (aided by the secondary inter-particle forces) and
also held the agglomerate against the perfusion flow. It was
found that a typical agglomerate of HACs could withstand
linear fluid velocities of up to approximately 1 mm s−1, thus
trapping the levitated agglomerate against the flow of contin-
uous perfusion.
Serum free chondrogenic culture medium held within a
reservoir was circulated around a closed loop by a peristaltic
pump (403U/VM2, Watson-Marlow, Falmouth, UK) and
Marprene tubing (505DZ/RL, Fisher Scientific, UK; ID
0.8 mm) at a rate of 1.32 ml h−1 (Fig. 1c). The serum-free
chondrogenic medium was composed of α-MEM supplemented
with 10 ng ml−1 rhTGF-β3 (PeproTech, London, UK), 100 μM
ascorbate-2-phosphate, 10 nM dexamethasone and 1X ITS
liquid supplement (10 μg ml−1 insulin, 5.5 μg ml−1 transferrin
and 5 ng ml−1 selenite premix). The loop included the reso-
nant chamber connected to the tubing via PDMS connectors
and a bubble trap in close proximity to the chamber to pre-
vent bubbles disrupting the levitated agglomerate. A syringe
pump enabled excess bubbles to be extracted from the
bubble trap; during the experiment this was run at a continu-
ous rate of 0.02 ml h−1. The optimum CO2 concentration was
maintained by preconditioning the chondrogenic medium in
a standard CO2 incubator for 24 h to allow gaseous equilib-
rium and creating a 5% CO2 atmosphere in the space above
the culture medium in the reservoir through introduction of
the gas via a HEPA filter with 0.22 μm pore size.
Another syringe pump was used to introduce cells into the
chamber via a dedicated inlet. A suspension of HACs
containing 1 × 106 cells was introduced at a rate of 1 ml min−1
with the ultrasound active. The perfusion peristaltic pump
was activated once stable agglomerates were formed. The sys-
tem was placed within a poly(methyl methacrylate)/PMMA
box covered with expanded polystyrene sheets for thermal
insulation and a custom heating controller circulated hot air
to maintain the ambient temperature at 36 °C. Although acti-
vation of the ultrasound was found to cause heating, at the
ambient temperature, the active region of the chamber
reached a steady 37.0 ± 0.5 °C. The multicellular agglomerates
were cultured within the acoustofluidic perfusion bioreactors
over a period of 21 days in serum-free chondrogenic medium
to promote cartilage formation. At the end of the cultureLab Chip, 2014, 14, 4475–4485 | 4477
Lab on a ChipPaperperiod, two grafts were labelled with Cell Tracker™ Green and
Ethidium homodimer-1, fixed in 4% paraformaldehyde (PFA)
overnight at 4 °C and used for histological analysis; three
grafts were used for determination of biomechanical proper-
ties and two grafts were harvested for implantation into par-
tial thickness chondral defects.4478 | Lab Chip, 2014, 14, 4475–4485
Fig. 1 Application of the acoustofluidic perfusion bioreactor for the gene
rectangular glass capillary (length 5 cm, ID 0.8 × 8 mm2, wall thickness
piezoelectric transducer (PZT), which was glued to the capillary. (b) Schem
the resonant chamber. The transducer generated an ultrasonic standing
acting as a reflector. At the resonant frequency (0.897 MHz) of the cavity
centre of the chamber. When cells suspended in culture medium were in
cells to the pressure node, where they aggregated rapidly and eventually f
of the chamber above the transducer. (c) Serum-free chondrogenic mediu
closed loop that included the resonant chamber, bubble trap and syringe
electrodes on the transducer were connected to a custom-made amplifier
sound caused heating, at the ambient temperature (36 °C) of the system, th2.3 Assessment of cell viability
Cell viability in the day 21 neocartilage grafts was examined
by ‘live-dead’ staining using a combination of CellTracker™
green/CTG CMFDA Ĳ5-chloromethylfluorescein diacetate)
and Ethidium homodimer-1/EH-1. Harvested samples wereThis journal is © The Royal Society of Chemistry 2014
ration of neocartilage grafts. (a) The bioreactor was fabricated using a
0.54 mm), polydimethylsiloxane (PDMS) connectors and a ceramic
atic diagram illustrating formation of the multicellular agglomerate in
wave field in the lumen of the capillary, with the upper glass surface
, a half-wavelength mode was established with a pressure node in the
troduced into the chamber, the acoustic radiation forces directed the
ormed the multicellular agglomerate, which was levitated in the lumen
m held in the reservoir was circulated by a peristaltic pump around a
pump used to introduce cells into the chamber. Wires soldered to the
that was driven by a signal generator. Although activation of the ultra-
e active region of the chamber reached a steady 37.0 ± 0.5 °C.
Lab on a Chip Paperwashed in PBS and incubated in 1 ml of CTG (10 μg ml−1)
and EH-1 (5 μg ml−1) solution for 45 min in a humidified
atmosphere at 37 °C, 5% CO2 and 21% O2. Samples were
then fixed in 4% PFA overnight at 4 °C. Viable cells (green)
and necrotic cells (red) were visualised in paraffin wax
sections of the constructs by fluorescence microscopy using a
Zeiss Axiovert 200 inverted fluorescence microscope (Carl
Zeiss, Cambridge, UK) and imaged using a CCD camera with
Axiovision software.
2.4 Ex vivo organ culture partial thickness cartilage
defect model
Near full-thickness articular cartilage pieces (1 × 1 cm2,
2 mm thick) were dissected from healthy non load-bearing
regions of human femoral heads. A partial thickness defect
(~2 × 2 mm2, 1 mm deep) was created in each articular carti-
lage piece with a sterile drill bit, taking extreme care to avoid
full penetration of the cartilage. One neocartilage graft was
implanted into each defect and the neocartilage graft-host
cartilage construct was then placed on a Millipore filter insert
(hydrophilic polytetrafluoroethylene/PTFE membrane, 0.4 μm
pore size, 6-well plate configuration) and cultured at air–
liquid interface in a humidified atmosphere at 37 °C, 5%
CO2 and 21% O2 for 16 weeks. Pieces of articular cartilage
with empty defects cultured similarly for 16 weeks served as
controls. The samples were harvested at 16 weeks, fixed in 4%
PFA overnight at 4 °C and processed for histological analysis.
2.5 Processing, embedding and section cutting
PFA-fixed samples were processed through graded ethanol
(50–100%) and histoclear (100%) prior to embedding in
paraffin wax. Sequential sections (7 μm) were cut on the
microtome and mounted on glass slides for histological and
immunohistochemical staining. Images were captured with
Olympus dotSlide virtual microscopy system (Olympus,
Southend-on-Sea, UK).
2.6 Alcian blue and Sirius red staining
Sections were stained with Alcian blue 8GX (5 mg ml−1 in 1%
(v/v) glacial acetic acid) and Sirius red F3B (10 mg ml−1 in
saturated picric acid) following nuclear staining with
Weigert's haematoxylin.
2.7 Immunohistochemistry
After quenching endogenous peroxidase activity with 3% (v/v)
H2O2 and blocking with 10 mg ml
−1 BSA in PBS, sections
were incubated with relevant primary antisera (diluted appro-
priately using 10 mg ml−1 BSA in PBS) at 4 °C overnight. This
was followed by hour-long incubation each with the appropriate
biotinylated secondary antibody and ExtrAvidin®-Peroxidase.
Visualisation of the immune complex was undertaken
using the avidin–biotin method linked to peroxidase and
AEC (3-amino-9-ethylcarbazole), resulting in a reddish brown
reaction product. Negative controls (omission of the primaryThis journal is © The Royal Society of Chemistry 2014antisera) were included in all immunohistochemistry proce-
dures. No staining was observed in the sections used as nega-
tive controls. Sections were counter-stained with Alcian blue.
The anti-SOX9 (AB5535, Millipore, Watford, UK) antibody was
used at dilution of 1 : 150 following the antigen retrieval pro-
cedure, which involved heating sections in 0.01 M citrate
buffer (pH 6.0) for 5 minutes before the application of the
standard immunohistochemistry procedure. Sections were
treated with type I hyaluronidase at 37 °C for 20 min in
order to unmask the collagen fibres and render them acces-
sible for immunostaining with the antibodies against the
three types of collagen. The anti-collagen type I antibody
(LF68 from Dr Larry Fisher, NIH, USA), anti-collagen type II
and anti-collagen type X antibodies (cat. no. 234187 and
234196, both sourced from Millipore, Watford, UK) were
used at dilutions of 1 : 1000, 1 : 500 and 1 : 100, respectively.
2.8 Indentation-type Atomic Force Microscopy (IT-AFM)
As described previously,43 cantilever-based IT-AFM with a
micrometre-sized spherical tip was used to measure the
microscale elastic moduli of day 21 neocartilage grafts
and full-thickness articular cartilage pieces, dissected from
femoral heads of patients (2 female and 1 male, average age:
77 years) who had suffered a fracture in the neck of femur.
In brief, hard borosilicate glass spheres (diameter: 10 μm;
02715-AB, SPI Supplies, West Chester, PA, USA) were glued
onto tipless rectangular silicon AFM cantilevers (spring
constant: 6.11 N m−1; type All In One-TL, BudgetSensors, Sofia,
Bulgaria) for probing the samples. Force volume maps of
load–displacement curves (16 × 16 i.e. 256 load–displacement
curves) were recorded in a regular grid over the sample surface.
Each individual set of data consisted of load–displacement
curves recorded at a rate of half full loading cycles per second
in a sample area of 10 μm × 10 μm. A maximum cantilever
deflection of 200 nm coupled with a maximum applied load
of 1.2 μN was used for the measurement of all samples. The
samples were fixed on a glass slide and submerged in PBS
during the measurements, which were performed at room
temperature using a MFP-3D AFM (Oxford Systems, Asylum
Research, Santa Barbara, CA, USA). Values for microscale
elastic moduli of the samples were calculated from the
unloading curves obtained from IT-AFM, ensuring that
the displacement data did not contain irreversible (i.e.
plastic) deformation. Statistical analysis was performed using
Mann–Whitney U test. Results were considered significant if
the probability of occurrence by random chance alone was
less than 5% (i.e. p < 0.05).
3. Results
3.1 Examination of day 21 grafts for assessment of cell
viability, cartilage formation and micromechanical properties
3-D membrane-like constructs (measuring ~2.5 × 2.5 mm2,
0.2 mm thick) were harvested from the acoustofluidic perfu-
sion bioreactors following the 21 day culture period. The con-
structs were labelled with Cell Tracker™ Green and EthidiumLab Chip, 2014, 14, 4475–4485 | 4479
Lab on a ChipPaperhomodimer-1 to determine metabolically viable and necrotic
cells, respectively. Intense green staining coupled with absence
of red staining in the sections indicated robust cell viability and
negligible cell necrosis within the constructs (Fig. 2a, b, m, n).
Sequential sections of the constructs were stained using a
range of routine histological and immunohistochemical tech-
niques for analysis of cartilage formation and chondrogenic
differentiation. Histological examination of the sections
revealed hyaline cartilage-like tissue composed of numerous
chondrocytes within lacunae embedded in dense extracellular
matrix constituted by proteoglycans and collagen, which were
stained with Alcian blue and Sirius red, respectively
(Fig. 2c, d, o, p). Extensive expression of SOX-9, the key
marker of chondrogenesis, was observed in most cells of the
constructs (Fig. 2e, f, q, r), along with immunostaining
for type II collagen, the hyaline cartilage-specific collagen,
in areas of collagenous matrix (Fig. 2g, h, s, t). Further immu-
nohistochemical analysis of the constructs confirmed negligi-
ble expression of type I collagen, a key constituent of
fibrocartilage and bone matrix (Fig. 2i, j, u, v), and type X
collagen, a phenotypic marker of hypertrophic cartilage
(Fig. 2k, l, w, x), in the extracellular matrix.4480 | Lab Chip, 2014, 14, 4475–4485
Fig. 2 Cell viability and chondrogenic differentiation in neocartilage gra
following the 21 day culture period in chondro inductive medium. (a,
and Ethidium homodimer-1 (live-dead staining) exhibited metabolically via
cells. (c, d, o, p) Histological sections of the grafts stained with Alcian
of chondrocytes in lacunae embedded in proteoglycan and collagen-rich
immunostaining sequential sections of the grafts with antibodies against
SOX-9 in chondrocytes and (g, h, s, t) type II collagen in the extracellular
while (k, l, w, x) lack of staining for type X collagen indicated absence of c
and high magnification images represent 200 μm and 50 μm respectively.The micromechanical properties of the neocartilage con-
structs were compared with full thickness human articular
cartilage. The values for microscale elastic moduli of the
neocartilage constructs and full thickness human articular
cartilage samples determined by IT-AFM were found to be
comparable (Fig. 3).3.2 Assessment of the quality of the repair tissue and its
integration with the native articular cartilage matrix in the
partial thickness chondral defect
The histology of the repair tissue, generated after 16 weeks of
implantation of the neocartilage construct into the partial
thickness defect of the host articular cartilage, was examined
in sections stained with Alcian blue and Sirius red. Following
16 weeks of co-culture, the implanted graft integrated into the
host articular cartilage and maintained the hyaline cartilage-
like morphology, characterised by numerous chondrocytes
embedded in dense proteoglycan matrix stained with Alcian
blue (Fig. 4a–c). The repair tissue (demarcated by dashed
lines in Fig. 4a), generated by the graft upon implantation
into the defect, was analogous to hyaline cartilage andThis journal is © The Royal Society of Chemistry 2014
fts of HACs harvested from the acoustofluidic perfusion bioreactors
b, m, n) Sections of the grafts labelled with Cell Tracker™ Green
ble cells that were stained fluorescent green and absence of necrotic
blue and Sirius red displayed hyaline cartilage-like tissue composed
extracellular matrix. Chondrogenic differentiation was examined by
the phenotypic proteins and confirmed by the presence of (e, f, q, r)
matrix. (i, j, u, v) Negligible staining was observed for type I collagen,
hondrocyte hypertrophy in the neocartilage grafts. Scale bars for low
Fig. 3 Micromechanical properties of human articular cartilage and
neocartilage grafts generated using the acoustofluidic perfusion
bioreactors were determined by IT-AFM. The difference between
values for microscale elastic moduli of full thickness human articular
cartilage samples and day 21 neocartilage grafts was not statistically
significant. Values are expressed as mean ± SD, n = 3 in each group.
Lab on a Chip Paperdemonstrated the presence of chondrocytes and proteoglycan-
rich extracellular matrix. Moreover, the repair tissue exhibited
close continuous attachment with the host cartilage and no
gaps were observed between the newly synthesized cartilage
and host articular cartilage along the boundary of the defect
(demarcated by dashed line in Fig. 4d). Representative image
of Alcian blue and Sirius red-stained section of the host articu-
lar cartilage with partial thickness defect after the 16 week
culture period without the neocartilage implant demonstrated
absence of cartilage regeneration (Fig. 4e).
4. Discussion
The present study represents the first successful application of
the novel microfluidic perfusion bioreactors with integrated
USWT to bioengineer robust, 3-D, scaffold-free neocartilage
grafts of HACs that are analogous to native hyaline cartilage.
Additionally, in an ex vivo organ culture model, the study has
demonstrated the potential of the neocartilage grafts to medi-
ate repair of partial thickness chondral defects by generation
of hyaline cartilage-like repair tissue. A scaffold-free tissue
engineering approach was employed by the present study,
instead of a scaffold-based approach, for the ex vivo genera-
tion of 3-D cartilage constructs. This is because, in compari-
son to the natural extracellular matrix, which aids cartilage
regeneration by providing crucial cues to chondrocytes, some
artificial scaffold materials may impair tissue formation and
defect regeneration due to their unpredictable degradation
rates and immunogenicity of the degradation products.44
While the pellet culture technique is an effective ex vivo
scaffold-free strategy to stimulate chondrogenic redifferentiation
of dedifferentiated chondrocytes and promote cartilage for-
mation in a high cell density 3-D microenvironment,45 it has
limited clinical application because conventional static pellet
culture is associated with lack of mechanical stimulation,
inefficient oxygen diffusion and suboptimal metabolite massThis journal is © The Royal Society of Chemistry 2014transfer rates, which adversely affect the scale-up, quality
(i.e. formation of fibrous versus hyaline cartilage) and biome-
chanical properties of the chondrospheres. This was demon-
strated in our previous study, where attempts to scale-up the
size of constructs by conventional static pellet culture using
1 × 106 HACs, resulted in the formation of chondrospheres
that were characterised by the development of necrotic cores
and suboptimal hyaline cartilage.46 Mass transport limita-
tions and oxygen diffusion gradients in the macroscopic
pellets have been recognised as significant obstacles to
robust chondrogenesis, thereby limiting the prospects of
macroscopic cartilaginous pellets/chondrospheres in the
repair of chondral defects.47
The scaffold-free grafts bioengineered in the acoustofluidic
perfusion bioreactors using 1 × 106 HACs exhibited distinct
hyaline cartilage-like tissue, which was characterised by the
robust expression of chondrogenic markers, namely SOX-9,
type II collagen and proteoglycans, coupled with negligible
expression of collagen types I and X. Previous studies have
demonstrated induction of type II collagen and proteoglycans
by human articular chondrocytes in 3-D alginate culture in
response to low intensity ultrasound, and suppression of
chondrocyte hypertrophy by inhibition of expression of type X
collagen due to low intensity ultrasound treatment.48,49
Although the exact mechanism by which ultrasound pro-
motes the expression of chondrogenic markers remains to be
fully elucidated, it has been suggested that excitation of
microbubbles or acoustic streaming produced by the ultra-
sound can modulate mechanoreceptor-mediated transmem-
brane signalling mechanisms (involving protein kinase C) for
the regulation of Aggrecan gene expression and stimulation
of subsequent proteoglycan synthesis.50–52 Moreover, both
cell shape and cytoskeletal organisation were shown to be
essential for initiation of Sox-9 expression and maintenance
of the differentiated chondrocyte phenotype in 2-D aggregates
of chick wing bud mesenchymal cells, which were generated
and levitated using an USWT.53
To enhance mass transfer and mechanical stimulation,
the current system employed two strategies, namely continu-
ous perfusion of the culture medium at rates considered low-
shear and sweeping acoustic drive frequencies over the range
of 890 to 910 kHz, at a sweep rate of 50 Hz. The sweep rate of
50 Hz reflected the maximum value available from the signal
generator that was used in the study. The application of fluid
shear from the perfusion system in our device compensated
for the reduced acoustically-induced forces exerted on the
cells by the ultrasonic waves. Mechanical stimulation
conveyed by the flow of the culture medium i.e. fluid
flow-induced shear, has been acknowledged as a crucial bio-
mechanical stimulus, which enhances chondrocyte function
and ex vivo cartilage formation by directly influencing cell
metabolism and extracellular matrix synthesis.13 Moreover,
chondrocytes respond positively to fluid convection, which
has been shown to promote the transport of molecules and
further improve cartilage formation due to enhanced mass
transfer rates of metabolites.54Lab Chip, 2014, 14, 4475–4485 | 4481
Fig. 4 Generation of repair tissue after 16 weeks of implantation of the neocartilage graft into the partial thickness defect created in the host
human articular cartilage. (a–c) The defect region in the host articular cartilage exhibited the presence of hyaline cartilage-like graft and repair
tissue (demarcated with dashed lines in a), composed of numerous chondrocytes embedded in dense proteoglycan-rich matrix stained with Alcian
blue. (d) The hyaline cartilage-like repair tissue fused closely with the host articular cartilage; the dashed line demarcated the boundary between
the repair tissue and native cartilage. (e) Representative image of an empty defect demonstrating absence of cartilage regeneration after 16 weeks
of culture under identical conditions. Scale bars represent 500 μm in a and e, and 50 μm in b–d.
Lab on a ChipPaperAs a significant departure from previous studies that
applied either low intensity pulsed ultrasound (1–1.5 MHz,
1 kHz repeat, 6–40 min) or intermittent low intensity diffuse
ultrasound (5 MHz excitation frequency) to stimulate
chondrocytes,20,29,51 in our study the ultrasound was
constantly applied over the 21 day culture period and swept
over a small range of frequencies, thereby exciting a range of
standing wave resonances in the capillary. Initially, the
frequency sweep was applied in order to facilitate multiple
devices (that were hand-assembled and hence, exhibited slight
differences in resonant frequencies) to be run simultaneously
from a single amplifier, and to allow for small changes in the
resonant frequency with time due to temperature fluctuations
and/or geometric changes of the transducers as a result of
autoclaving. The range (890–910 kHz) was chosen so as to
include the half-wavelength resonant frequencies of the three
devices (897, 899 and 902 kHz). However, an additional effect4482 | Lab Chip, 2014, 14, 4475–4485is observed that warrants further investigation in the future:
the frequency sweeping caused the agglomerates to vibrate/
oscillate at the sweep frequency of 50 Hz, resulting in the
application of additional fluidic shear stresses to the agglom-
erates. This effect was more easily observed at lower sweep fre-
quencies, at which it was apparent that each individual
frequency of the sweep range created a slightly different reso-
nance and related trapping position. At lower sweep frequen-
cies e.g. when the sweep frequency was reduced to 1 Hz, the
cell agglomerates were observed to oscillate with ~1 mm
vibration amplitude. Based on these preliminary observa-
tions, we hypothesise that the mechanical stimulation pro-
vided by the vibration applied to the cell agglomerates, in
addition to the fluid shear from continuous perfusion of the
chondrogenic culture medium, may be crucial for stimulating
robust chondrogenesis and hyaline cartilage formation in the
agglomerates. Further work is however required to optimiseThis journal is © The Royal Society of Chemistry 2014
Lab on a Chip Paperthe sweep rate, quantify the mechanical forces acting on the
agglomerates and examine their effects in detail on cartilage
formation by the cells of the agglomerates.
When ultrasound is absorbed by a material, its mechanical
energy is primarily converted into heat. The acoustofluidic
perfusion bioreactors in the present study are custom-built
using glass capillaries and filled with culture medium, both
of which are ‘low-loss materials’. Moreover, the capillary con-
struction limits transmission of the ultrasound into the
surrounding structure, thereby resulting in a high resonant
Q-factor. Hence, it is possible to generate a substantial acous-
tic field without significant heating.55 The steady state tem-
perature rise recorded by the thermocouple embedded within
our device was 0.8 °C. Additionally, in the current experimen-
tal setup, a custom made incubator incorporating a fan and
thermostatic control maintained the environmental tempera-
ture at around 36 °C, thus ensuring the optimal cell culture
temperature close to 37 °C in the active region of the bioreac-
tor. Prolonged exposure to ultrasound in the acoustofluidic
perfusion bioreactor therefore did not adversely affect cell
viability, as confirmed by the presence of metabolically
active viable cells and absence of necrotic cells in day 21
neocartilage explants.
To determine the micromechanical properties of the
neocartilage grafts, elastic moduli of the bulk material of day
21 grafts were measured using an IT-AFM microtip (spherical
indenter diameter of 10 μm), and compared to the elastic
moduli of freshly isolated full-thickness human articular car-
tilage pieces. Previous work has reported that the microscale
elastic modulus of human articular cartilage, determined
using IT-AFM, is 1.3 MPa regardless of the degree of OA,
while changes due to aging and/or OA are only depicted at
the nanometer scale.43 Harnessing a similar IT-AFM setup,
we obtained comparable value for elastic modulus [1.34 ±
0.315 MPa] of the full-thickness human articular cartilage
pieces utilised in the present study. Interestingly, the elastic
modulus [0.90 ± 0.372 MPa] of day 21 neocartilage grafts was
similar to the elastic modulus of human articular cartilage.
Thus, the neocartilage constructs were not only histologically
comparable to hyaline cartilage, but also displayed compara-
ble mechanical competency as native articular cartilage.
An ex vivo organ culture partial thickness cartilage defect
model was utilised in the present study to determine the abil-
ity of the neocartilage explants to integrate with native
human articular cartilage and repair the defects. Integration
is defined as the absence of gaps between the surface of the
repair tissue generated by the cartilage graft and the border
of the native cartilage matrix in the defect region.56 Often
after implantation, cartilaginous grafts do not integrate read-
ily or predictably with the host tissue to form a continuous
mechanically stable attachment. This largely occurs because
the repair tissue is predominantly composed of fibrocartilage,
which is deficient in proteoglycans and mechanically inferior,
compared to the host hyaline cartilage.57 In the present
study, following implantation of the neocartilage graft into
the chondral defect and co-culture for 16 weeks ex vivo, theThis journal is © The Royal Society of Chemistry 2014defect was filled with hyaline cartilage-like tissue characterised
by the presence of numerous chondrocytes embedded in
dense proteoglycan matrix. Although a discernible boundary
was visible, no gaps were observed between the edge of the
repair tissue and the border of the defect in the host cartilage.
This was indicative of continuous close attachment between
the newly synthesized hyaline cartilage-like repair tissue and
the host articular cartilage, and integration of the repair tis-
sue into the surrounding native cartilage. Thus, implantation
of the neocartilage graft into the chondral defect resulted in
the generation of hyaline cartilage-like repair tissue that con-
tributed to significant improvements to the tissue architec-
ture within the defect, in comparison to absence of cartilage
regeneration in the empty defect. Further investigations will
focus on examining the biomechanical properties of the
repair tissue.
We acknowledge the limitations of the ex vivo organ
culture partial thickness cartilage defect model used in our
study to reproduce the complex biological and mechanical
environment of the joint. Since constructs demonstrate a cer-
tain threshold of function in vitro, to carry out a realistic
assessment of their potential for cartilage repair, we recog-
nise that they should be assayed in a large animal (e.g. lapine
model) load-bearing environment.9 Future work will therefore
involve implantation of the neocartilage grafts in partial
thickness chondral defects created in rabbit lateral femoral
condyles and long-term assessment of the repair tissue post-
implantation.
5. Conclusions
In summary, we have successfully applied a novel tissue engi-
neering approach that combines microfluidic perfusion bio-
reactor technology with continuous application of ultrasound
to bioengineer scaffold-free (hence devoid of any foreign
material) neocartilage grafts, which are analogous to native
hyaline cartilage both histologically and biomechanically,
and have the ability to repair partial thickness chondral
defects. The work therefore presents a real opportunity to
derive a robust tissue-based product, which has the potential
for subsequent use in restorative approaches, such as II
generation ACI, for the repair of focal partial thickness
chondral defects in early stage OA.
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